Jun
07
Valeant Shakes Confidence, Again, in Attempt to Do Opposite
By-
Shares down 15% after new CEO tries to explain lower sales
-
Valeant files 10-Q report, avoiding nearest risk of default
What’s the deal with Valeant Pharmaceuticals International Inc. and conference calls?
After just a month on the job, Chief Executive Officer Joe Papa tried to explain to analysts on Tuesday why sales numbers were so dismal for some key drug categories and why he didn’t expect them to get much better this year.
Papa didn’t go into enough detail to make investors comfortable. Instead, he urged analysts to look at “adjusted earnings” — a measure to which management, to an extent, can add or subtract items at its discretion…
Valeant Shakes Confidence, Again, in Attempt to Do Opposite
